CVS Health Delivering on Commitment to Establish up to 1,000 COVID-19 Test Sites by End of May

May 14, 2020

CVS Health will open more than 50 COVID-19 test sites at select CVS Pharmacy drive-thru locations across Arizona, Connecticut, Florida, Massachusetts and Pennsylvania on May 15, 2020.

CVS notes the opening of hundreds of additional test sites across the country will be announced over the next two weeks.

The new sites will utilize self-swab tests and mark the next phase of the company’s COVID-19 testing strategy, announced April 27 at the White House. CVS Health expects to have up to 1,000 locations across the country offering this service by the end of May, with the goal of processing up to 1.5 million tests per month, subject to availability of supplies and lab capacity. The company currently operates large-scale rapid test sites in coordination with five states, which can process a total of nearly 30,000 tests per week.

“While the large-scale test sites we’ve been operating since early April have proven successful, this new approach allows us to utilize our presence in communities across the country and bring testing closer to home,” said Larry J. Merlo, President and CEO, CVS Health. “Our frontline employees will continue to play a critical role in the testing process, with members of their communities directly benefitting from their dedication and selflessness.”

Self-swab tests will be available to individuals meeting Centers for Disease Control and Prevention criteria, in addition to age guidelines. Patients must register in advance at CVS.com beginning Friday, May 15 to schedule an appointment. Patients will be required to stay in their cars and directed to the pharmacy drive-thru window where they will be provided with a test kit and given instructions; a CVS Pharmacy team member will observe the self-swab process to ensure it is done properly. Tests will be sent to an independent, third-party lab for processing and the results will be available in approximately three days.

Testing will not take place inside any retail locations, and CVS Pharmacy, HealthHUB and MinuteClinic will continue to serve customers and patients.

More information on steps CVS Health has taken to address the COVID-19 pandemic, including support for health care providers and clinicians facing financial and administrative strain, is available at the company’s frequently updated COVID-19 resource center.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”